The Beneficial Effect of 3-Month-Induction Therapy with Corticosteroids and Mycophenolate Mofetil Followed by Maintenance Therapy with Yearly Rituximab Infusions as Sole Maintenance Therapy in Cryptogenic Chronic Hypersensitivity Pneumonitis
Background: The available data on cryptogenic chronic hypersensitivity pneumonitis (ccHP) indicate an inherited predisposition to disease with triggering autoimmune phenomena. Hence, we evaluated prospectively the role of a new autoimmune regimen in treatment of its severe and progressive disease. Patients and Methods: A total of 9 patients were included in the study. They had criteria for ccHP viz. 1) clinical features of cryptogenic progressive restrictive lung disease, 2) high-resolution computed tomographic pulmonary abnormalities, and 3) bronchoalveolar lavage lymphocytosis (>30%). The regimen consisted of an initial induction phase of 3-month Solumedrol 1 g IV daily for 3 days followed by 1 month of Prednisone (P) 60 mg/day to tapered down to discontinuation by 3rd month. They also had received Mycophenolate mofetil (MMF) 1 g twice daily for 3 months. This stage was followed by a maintenance phase of yearly Rituximab infusions (1 g followed by 1 g 2 weeks later). Results: compared to their previous 6 months deterioration; all patients showed significant improvement in their forced vital volume, diffusion capacity for carbon monoxide, 6-minutes-walk after the induction phase (at 3 months) which improved further at 15 months with Rituximab therapy. Conclusion: After 3-month induction therapy with P and MMF; yearly R treatment is a safe, practical and effective long-term therapy for ccHP.
References
[1]
Vasakova, M., Morell, F., Walsh, S., Leslie, K. and Raghu, G. (2017) Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 196, 680-689. https://doi.org/10.1164/rccm.201611-2201PP
[2]
Mokhlis, J., Robertson, A.S., Moore, V.C., Burge, P.S. and Walters, G.I. (2017) Distribution of Occupational and Non-Occupational Causes in Hypersensitivity Pneumonitis Diagnosed by an Interstitial Lung Disease Expert Panel. Thorax, 72, A64-A65. https://doi.org/10.1136/thoraxjnl-2017-210983.112
[3]
Morell, F., Villar, A., Montero, M.á., Munoz, X., Colby, T.V., et al. (2013) Chronic Hypersensitivity Pneumonitis in Patients Diagnosed with Idiopathic Pulmonary Fibrosis: A Prospective Case-Cohort Study. The Lancet Respiratory Medicine, 1, 685-694. https://doi.org/10.1016/S2213-2600(13)70191-7
[4]
Jin, B.B., Xu, W.B., Peng, M., Shi, J.H., Tian, X.L., et al. (2013) Clinical Characteristic Analysis of 96 Cases of Hypersensitivity Pneumonitis. Chinese Journal of Tuberculosis and Respiratory Diseases, 36, 83-87.
[5]
Fernandez Perez, E.R., Kong, A.M., Raimundo, K., Koelsch, T.L., Kulkarni, R. and Cole, A.L. (2018) Epidemiology of Hypersensitivity Pneumonitis among an Insured Population in the United States: A Claims-Based Cohort Analysis. Annals of the American Thoracic Society, 15, 460-469. https://doi.org/10.1513/AnnalsATS.201704-288OC
[6]
Barber, C.M., Wiggans, R.E., Carder, M. and Agius, R. (2017) Epidemiology of Occupational Hypersensitivity Pneumonitis; Reports from the SWORD Scheme in the UK from 1996 to 2015. Occupational and Environmental Medicine, 74, 528-530.
[7]
De Sadeleer, L.J., Hermans, F., De Dycker, E., Yserbyt, J., Verschakelen, J.A., et al. (2018) Effects of Corticosteroid Treatment and Antigen Avoidance in a Large Hypersensitivity Pneumonitis Cohort: A Single-Centre Cohort Study. Journal of Clinical Medicine, 8, Article 14. https://doi.org/10.3390/jcm8010014
[8]
Adegunsoye, A., Oldham, J.M., Fernández Pérez, E.R., Hamblin, M., Patel, N., et al. (2017) Outcomes of Immunosuppressive Therapy in Chronic Hypersensitivity Pneumonitis. European Respiratory Journal Open Research, 3, 00016-2017. https://doi.org/10.1183/23120541.00016-2017
[9]
Ferreira, M., Borie, R., Crestani, B., Rigaud, P., Wemeau, L., et al. (2020) Efficacy and Safety of Rituximab in Patients with Chronic Hypersensitivity Pneumonitis (cHP): A Retrospective, Multicentric, Observational Study. Respiratory Medicine, 172, Article ID: 106146. https://doi.org/10.1016/j.rmed.2020.106146
[10]
Ojanguren, I., Villar, A., Ramon, M.A., Cruz, M.J., Munoz, X., et al. (2015) Rituximab for the Treatment of Chronic Hypersensitivity Pneumonitis. European Respiratory Journal, 46, PA815. https://doi.org/10.1183/13993003.congress-2015.PA815
[11]
Samarghitean, C., Valiaho, J., Vihiaho, J. and Vihinen, M. (2004) Online Registry of Genetic and Clinical Immunodeficiency Diagnostic Laboratories, ID Diagnostics. Journal of Clinical Immunology, 24, 53-61. https://doi.org/10.1023/B:JOCI.0000018063.55963.0c
[12]
Leone, P.M. and Richeldi, L. (2020) Current Diagnosis and Management of Hypersensitivity Pneumonitis. Tuberculosis and Respiratory Diseases, 83, 122-131. https://doi.org/10.4046/trd.2020.0012
[13]
Raghu, G., Remy-Jardin, M., Ryerson, C.J., Myers, J.L., Kreuter, M., et al. (2020) Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 202, e36-e69.
[14]
Kimby, E. (2005) Tolerability and Safety of Rituximab (MabThera). Cancer Treatment Review, 31, 456-473. https://doi.org/10.1016/j.ctrv.2005.05.007
[15]
Genentech (2008) Rituxan: Highlights of Prescribing Information.
[16]
El-Reshaid, K., Sallam, H., Hakim, A. and Al-Attiyah, R. (2012) Rituximab in Treatment of Idiopathic Glomerulopathy. Saudi Journal of Kidney Diseases and Transplantation, 23, 973-978. https://doi.org/10.4103/1319-2442.100878
[17]
El-Reshaid, K., El-Reshaid, W., Al-Bader, S., Sallam, H.T., Hakim, A. and Al-Attiyah, R. (2018) New Protocols for Treatment of Class IV Lupus Nephritis with Emphasis on Rituximab as the Sole Maintenance Therapy. Kuwait Medical Journal, 50, 343-350.
[18]
El-Reshaid, K. and Al-Bader, S. (2021) Massive and Unilateral Rheumatoid Pleural Effusion without Overt Disease. International Journal of Case Reports and Images, 12, Article ID: 101277Z01KR2021. https://doi.org/10.5348/101277Z01KR2021CR
[19]
El-Reshaid, K. and Al-Bader, S. (2019) Rituximab Treatment for Recurrent Skin Vasculitis Due to Cryoglobulinemia Associated with Hepatitis C Despite Viral Clearance with Sofosbuvir. International Journal of Medical Research Professionals, 5, 86-88.
[20]
Muhammad, K., Roll, P., Einsele, H., Dorner, T. and Tony, H.P. (2009) Delayed Acquisition of Somatic Hypermutations in Repopulated IgD+CD27+ Memory B Cell Receptors after Rituximab Treatment. Arthritis and Rheumatology, 60, 2284-2293. https://doi.org/10.1002/art.24722
[21]
Ley, B., Newton, C.A., Arnould, I., Elicker, B.M., Henry, T.S., et al. (2017) The MUC5B Promoter Polymorphism and Telomere Length in Patients with Chronic Hypersensitivity Pneumonitis: An Observational Cohort-Control Study. The Lancet Respiratory Medicine, 5, 639-647. https://doi.org/10.1016/S2213-2600(17)30216-3
[22]
Agostini, C., Trentin, L., Facco, M. and Semenzato, G. (2004) New Aspects of Hypersensitivity Pneumonitis. Current Opinion in Pulmonary Medicine, 10, 378-382. https://doi.org/10.1097/01.mcp.0000133067.71469.b2
[23]
Aquino-Galvez, A., Camarena, A., Montano, M., Juarez, A., Zamora, A.C., Gonzalez-Avila, G., et al. (2008) Transporter Associated with Antigen Processing (TAP) 1 Gene Polymorphisms in Patients with Hypersensitivity Pneumonitis. Experimental and Molecular Pathology, 84, 173-177. https://doi.org/10.1016/j.yexmp.2008.01.002
[24]
Flaherty, K.R., Wells, A.U., Cottin, V., et al. (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. The New England Journal of Medicine, 381, 1718-1727. https://doi.org/10.1056/NEJMoa1908681
[25]
Mateos-Toledo, H., Mejía-ávila, M., Rodríguez-Barreto, ó., Mejía-Hurtado, J.G., Rojas-Serrano, J., et al. (2020) An Open-Label Study with Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos de Bronconeumología (English Edition), 56, 163-169. https://doi.org/10.1016/j.arbr.2019.08.008
